TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07779616: A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PTC844 in Participants With Active Rheumatoid Arthritis

Sponsor: PTC Therapeutics · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 75 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07779616 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07779616 Rescue Dossier →